Epidermal growth factor inhibition in solid tumours

Apar Kishor Ganti, Anil Potti

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations


The epidermal growth factor receptor (EGFR) plays an important role in the carcinogenesis of many human malignancies and is therefore an attractive target against which anticancer therapy may be effective. At present, there are two ways in which this may be achieved clinically: antibodies against EGFR and inhibitors of the EGFR tyrosine kinase. This review describes presently approved agents cetuximab (monoclonal EGFR antibody), gefitinib and erlotinib (EGFR tyrosine kinase inhibitors) in detail. Efficacy data for these agents in various human malignancies is presented. Various other agents that are in the early stages of development at present have also been mentioned.

Original languageEnglish (US)
Pages (from-to)1165-1174
Number of pages10
JournalExpert Opinion on Biological Therapy
Issue number9
StatePublished - Sep 2005


  • Cetuximab
  • EGFR antibodies
  • EGFR inhibitors
  • EGFR tyrosine kinase inhibitors
  • Erlotinib
  • Gefitinib

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry


Dive into the research topics of 'Epidermal growth factor inhibition in solid tumours'. Together they form a unique fingerprint.

Cite this